← Back to Clinical Trials
Recruiting NCT04997109

NCT04997109 Telemedicine in Early Childhood Constraint Therapy in Cerebral Palsy

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04997109
Status Recruiting
Phase
Sponsor Emory University
Condition Cerebral Palsy
Study Type INTERVENTIONAL
Enrollment 267 participants
Start Date 2022-02-23
Primary Completion 2026-08-31

Eligibility & Interventions

Sex All sexes
Min Age 4 Months
Max Age 13 Months
Study Type INTERVENTIONAL
Interventions
APPLES-teleParent-centered Approach (PCA) Support InterventionStandard of Care

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 267 participants in total. It began in 2022-02-23 with a primary completion date of 2026-08-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study assesses two active treatments in different sequences and a standard of care group among infants with cerebral palsy.

Eligibility Criteria

Inclusion Criteria: * Aged 4 to 13 months, corrected age * Diagnosis of CP or classification of high-risk for CP as determined by published guidelines (\>95% risk of later CP) * Hammersmith Infant Neurological Exam (HINE) arm asymmetry score of greater than or equal to 2 and/or neuroimaging consistent with perinatal involvement * Hand Assessment for Infants (HAI) difference between hands ≥2, with an observable and relative difference in quality or amount of movement between hands, as determined by HAI-certified study therapists and/or a unimanual Bayley score difference between hands \>1 * Parent/legal guardian is able to provide informed consent Exclusion Criteria: * Congenital malformation of the brain or musculoskeletal system (MSK) * Receipt of botulinum toxin to the affected extremity within 3 months of study entry * Any prior long-term hard constraint programs

Contact & Investigator

Central Contact

Nathalie Maitre, MD, PhD

✉ nathalie.linda.maitre@emory.edu

📞 (678) 476-5332

Principal Investigator

Nathalie Maitre, MD, PhD

PRINCIPAL INVESTIGATOR

Emory University

Frequently Asked Questions

Who can join the NCT04997109 clinical trial?

This trial is open to participants of all sexes, aged 4 Months or older, up to 13 Months, studying Cerebral Palsy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04997109 currently recruiting?

Yes, NCT04997109 is actively recruiting participants. Contact the research team at nathalie.linda.maitre@emory.edu for enrollment information.

Where is the NCT04997109 trial being conducted?

This trial is being conducted at Atlanta, United States, Baltimore, United States, Philadelphia, United States, Salt Lake City, United States.

Who is sponsoring the NCT04997109 clinical trial?

NCT04997109 is sponsored by Emory University. The principal investigator is Nathalie Maitre, MD, PhD at Emory University. The trial plans to enroll 267 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology